EIC Investor Day@Nasdaq 7th of March, Stockholm

Evelina Vågesjö pitching the company at the Nasdaq event. The five minutes pitch was followed by questions and answers from a specialised jury.

Pitching Ilya Pharma at Evonik 2019

Evelina Vågesjö was presenting at Evonik HQ at an EIC Corporate Day, the 6th of February, in Essen Germany. Out of 4000 applicants sixteen companies were hand picked by Evonik to present their innovations and businesses. Ilya Pharma was one of the chosen companies.

Ilya Pharma is opening a new indication and recruits a post doctoral scientist with focus on IBD

A Postdoctoral Research Scientist position is available as part of a collaboration between Professor Mia Phillipson and Ilya Pharma AB aiming to develop novel therapeutics to treat inflammatory bowel disease.

Ilya Pharma is presenting at "INNOVATIONS IN WOUND HEALING 2018" FL 6-9 dec.

Selected Top 80 globally of emerging companies in deep tech, Hello Tomorrow challenge

Ilya Pharma raises additional Euro 3 million to take novel ATMP through to Phase II for wound care

Ilya Pharma raises additional Euro 3 million to take novel ATMP through to Phase II for wound care

A platform for new biologics and technology innovations

A high-quality, pilot-scale biopharmaceutical manufacturing facility is now opening in Uppsala, Sweden. The new Testa Center at GE Healthcare is both a national and an international test bed for start-up companies working with technology- and biologics innovations, as well as for the bioprocess industry. Ilya Pharma will be one of the first companies to use the bioprocess equipment.

ILYA Pharma is growing and recruiting

Want to work with drug development of an innovative medical product being a living organism?

ILYA Pharma will present at the Nordic Life Science Days

Ilya Pharma will give a presentation of the latest developments and the coming milestones in Stockholm September 11 2018.

Celebration of safety- and efficacy data from the last preclinical study

Ilya Pharma celebrates a good year and especially that the last preclinical study in mini pigs was successful and met safety aspects and that the treatment with ILP100 accelerates wound healing and reduces scaring in this model.